Aktis Oncology Stock Forecast
NASDAQ: AKTSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 18.15 0.00%
AKTS analyst consensus
Consensus (10 analysts)
strong_buy
Avg. price target
$35.39+94.99%
- Strong buy 1
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 10 Wall Street analysts covering Aktis Oncology (2026-10-08), 10 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $35.39, with a high estimate of $40.00 and a low estimate of $31.50. The average target implies upside of 95.0% from the current price of $18.15.
The spread between the highest and lowest targets is 27.0%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for AKTS.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 10% |
| Buy | 9 | 90% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $31.50 | +73.55% |
| Average target | $35.39 | +94.99% |
| High target | $40.00 | +120.39% |